drugset
drugset / Trial / NCT05174013

Safety, Tolerability, Pharmacokinetics and Target Engagement of GSK3858279 in Healthy Caucasian, Chinese and Japanese Participants

NCT05174013 ↗

Phase 1 Completed 33 enrolled GlaxoSmithKline
RandomizedSequentialDouble-blindTreatment

Summary

The purpose of this study is to evaluate the safety, tolerability, pharmacokinetics (PK), target engagement (TE) and immunogenicity of GSK3858279 when administered to healthy Caucasian, Chinese and Japanese participants.

Timeline

Start
2022-02-14
Primary completion
2023-02-10
Completion
2023-04-17

Drugs

EvaluationDrugModalityDoseRoute
Subject DENRAKIBART Monoclonal antibody 240 mg Subcutaneous

Indications

No indication recorded.